ES2065846A1 - Pharmaceutical formulation based on a steroidal or non- steroidal anti-inflammatory agent and an antibiotic belonging to the DNA Girase inhibitors group for topical ophthalmic use - Google Patents

Pharmaceutical formulation based on a steroidal or non- steroidal anti-inflammatory agent and an antibiotic belonging to the DNA Girase inhibitors group for topical ophthalmic use

Info

Publication number
ES2065846A1
ES2065846A1 ES09300826A ES9300826A ES2065846A1 ES 2065846 A1 ES2065846 A1 ES 2065846A1 ES 09300826 A ES09300826 A ES 09300826A ES 9300826 A ES9300826 A ES 9300826A ES 2065846 A1 ES2065846 A1 ES 2065846A1
Authority
ES
Spain
Prior art keywords
steroidal
girase
dna
inflammatory agent
steroidal anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09300826A
Other languages
Spanish (es)
Other versions
ES2065846B1 (en
Inventor
Wie Bergamini Michael Van
Mas Jose Alberto Vallet
Laguens Carmen Oros
Cabrera Antonio Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES9300826A priority Critical patent/ES2065846B1/en
Publication of ES2065846A1 publication Critical patent/ES2065846A1/en
Application granted granted Critical
Publication of ES2065846B1 publication Critical patent/ES2065846B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical formulation based on a steroidal or non- steroidal anti-inflammatory agent and an antibiotic belonging to the DNA Girase inhibitors group for topical ophthalmic use. It comprises: 0.001-5.0% of a steroidal or non-steroidal anti-inflammatory agent or an isomer, or an ester, or one of the pharmaceutically acceptable salts thereof 0.05-5.0% of a DNA Girase inhibitor, or an isomer, or an ester or one of the pharmaceutically acceptable salts thereof and optionally, one or more ingredients selected from isotonizing agents, pH buffers, viscosifiers, wetting agents, chelating agents, antioxidants and/or preservatives, in addition to one or more excipients appropriate for the form of pharmaceutical presentation of the formulation. Said formulation has a pH between 4 and 9. Application in the treatment of ocular inflammatory processes accompanied by infection.
ES9300826A 1993-04-20 1993-04-20 PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE. Expired - Fee Related ES2065846B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9300826A ES2065846B1 (en) 1993-04-20 1993-04-20 PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9300826A ES2065846B1 (en) 1993-04-20 1993-04-20 PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE.

Publications (2)

Publication Number Publication Date
ES2065846A1 true ES2065846A1 (en) 1995-02-16
ES2065846B1 ES2065846B1 (en) 1995-10-01

Family

ID=8281527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9300826A Expired - Fee Related ES2065846B1 (en) 1993-04-20 1993-04-20 PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE.

Country Status (1)

Country Link
ES (1) ES2065846B1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2105971A1 (en) * 1995-08-02 1997-10-16 S A L V A T Lab Sa Antibiotic/anti-inflammatory composition for otic application.
WO1999002130A3 (en) * 1997-07-11 1999-08-12 Mann Gerhard Chem Pharm Fab Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
EP0856310A3 (en) * 1997-02-04 2000-01-19 Senju Pharmaceutical Co., Ltd. Method for stabilizing acriylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized acrylcarboxylic acid
WO2001008689A1 (en) * 1999-07-30 2001-02-08 Allergan Sales, Inc. Ophthalmic compositions containing antibiotics and nsaids
WO2001022936A1 (en) * 1999-09-24 2001-04-05 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
US7514451B2 (en) 2003-09-10 2009-04-07 Kyorin Pharmaceutical Co., Ltd. 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
EP2502616A1 (en) * 2011-03-21 2012-09-26 Matthew Krayenbuhl Pharmaceutical nasal composition
US8846650B2 (en) 2001-09-21 2014-09-30 Novartis Ag Method of treating middle ear infections
US8920820B2 (en) 2001-12-12 2014-12-30 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9956288B2 (en) 2000-06-20 2018-05-01 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222407B2 (en) 2007-05-24 2012-07-17 Kyorin Pharmaceutical Co., Ltd. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844902A (en) * 1987-02-17 1989-07-04 Bayer Aktiengesellschaft Topically applicable formulations of gyrase inhibitors in combination with corticosteroids
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
WO1991017746A1 (en) * 1990-05-21 1991-11-28 Norwich Eaton Pharmaceuticals, Inc. The use of phenylpropanolamine as a mucus secretagogue in the upper airways

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844902A (en) * 1987-02-17 1989-07-04 Bayer Aktiengesellschaft Topically applicable formulations of gyrase inhibitors in combination with corticosteroids
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
WO1991017746A1 (en) * 1990-05-21 1991-11-28 Norwich Eaton Pharmaceuticals, Inc. The use of phenylpropanolamine as a mucus secretagogue in the upper airways

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2105971A1 (en) * 1995-08-02 1997-10-16 S A L V A T Lab Sa Antibiotic/anti-inflammatory composition for otic application.
EP1389469A1 (en) * 1997-02-04 2004-02-18 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
EP0856310A3 (en) * 1997-02-04 2000-01-19 Senju Pharmaceutical Co., Ltd. Method for stabilizing acriylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized acrylcarboxylic acid
US7320985B2 (en) 1997-02-04 2008-01-22 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
WO1999002130A3 (en) * 1997-07-11 1999-08-12 Mann Gerhard Chem Pharm Fab Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
WO2001008689A1 (en) * 1999-07-30 2001-02-08 Allergan Sales, Inc. Ophthalmic compositions containing antibiotics and nsaids
EP1688144A1 (en) * 1999-07-30 2006-08-09 Allergan, Inc. Ophthalmic compositions containing quinolone-antibiotics
JP2003505511A (en) * 1999-07-30 2003-02-12 アラーガン・セイルズ・インコーポレイテッド Ophthalmic compositions containing antibiotics and NSAIDs
AU777245B2 (en) * 1999-07-30 2004-10-07 Allergan, Inc. Ophthalmic compositions containing antibiotics and NSAIDS
US6548497B2 (en) 1999-07-30 2003-04-15 Allergan Sales, Inc. Methods of reducing non-inflammatory pain
US6552020B1 (en) 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
US6359016B2 (en) 1999-09-24 2002-03-19 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
WO2001022936A1 (en) * 1999-09-24 2001-04-05 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
JP2003510263A (en) * 1999-09-24 2003-03-18 アルコン，インコーポレイテッド Topical suspension formulation containing ciprofloxacin and dexamethasone
KR100722502B1 (en) * 1999-09-24 2007-05-28 알콘, 인코퍼레이티드 Topical suspension formulations containing ciprofloxacin and dexamethasone
US6284804B1 (en) 1999-09-24 2001-09-04 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
US9993557B2 (en) 2000-06-20 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US9956288B2 (en) 2000-06-20 2018-05-01 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US9149486B2 (en) 2001-09-21 2015-10-06 Alcon Pharmaceuticals Ltd Method of treating middle ear infections
US8846650B2 (en) 2001-09-21 2014-09-30 Novartis Ag Method of treating middle ear infections
US9402805B1 (en) 2001-09-21 2016-08-02 Alcon Pharmaceuticals Ltd. Method of treating middle ear infections
US10098891B2 (en) 2001-12-12 2018-10-16 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8920820B2 (en) 2001-12-12 2014-12-30 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US7514451B2 (en) 2003-09-10 2009-04-07 Kyorin Pharmaceutical Co., Ltd. 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
US8106072B2 (en) 2003-09-10 2012-01-31 Kyorin Pharmaceutical Co., Ltd. 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US9186296B2 (en) 2009-10-12 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9943486B2 (en) 2010-05-05 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2012127407A1 (en) * 2011-03-21 2012-09-27 Dos Santos, Antonio Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid
EP2502616A1 (en) * 2011-03-21 2012-09-26 Matthew Krayenbuhl Pharmaceutical nasal composition

Also Published As

Publication number Publication date
ES2065846B1 (en) 1995-10-01

Similar Documents

Publication Publication Date Title
ES2065846A1 (en) Pharmaceutical formulation based on a steroidal or non- steroidal anti-inflammatory agent and an antibiotic belonging to the DNA Girase inhibitors group for topical ophthalmic use
ES2079994A1 (en) Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use.
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
MX9606501A (en) Antifungal-wound healing compositions and methods for preparing and using same.
ES2094906T3 (en) COMPOSITIONS FOR THE TOPIC ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS.
CA2218619A1 (en) Antibacterial-wound healing compositions and methods for preparing and using same
ES2144119T3 (en) USE OF NON-STEROID CYCLOOXYGENASE INHIBITORS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HIGH INTRAOCULAR PRESSURE.
DE60134349D1 (en) Synergistic combinations containing a renin inhibitor for cardiovascular diseases
CA2304958A1 (en) Bioadhesive compositions and methods for topical administration of active agents
MX9803809A (en) Biphenyl hydroxamate inhibitors of matrix metalloproteinases.
WO2003004098A8 (en) Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
DK1293207T3 (en) Use of ritonavir (ABT-538) to improve the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
MX9606502A (en) Antikeratolytic-wound healing compositions and methods for preparing and using same.
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
MX9603596A (en) Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds.
AU7263591A (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors
EP1695711A3 (en) Parenteral formulations comprising boronic acid species for selective thrombin inhibition
ES2136252T3 (en) TREATMENT OF DISEASES CAUSED BY SEBACEA GLAND DISORDERS THROUGH THE USE OF ACIL COA CHOLESTEROL ACIL TRANSFERASE INHIBITORS.
BR9813319A (en) Compound, pharmaceutical composition for treating bacterial infections, and processes for treating bacterial infections and for preparing a compound
ITMI931326A1 (en) LIQUID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING 2- (4-ISOBUTYLPHENYL) PROPIONIC ACID
RS49599B (en) Use of h+, k+ -atpaze inhibitors and glucocortifoids and pharmaceutical formulation
CA2042972A1 (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
ES2078175A1 (en) Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof.
CA2417935A1 (en) Anti-inflammatory medicament

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20101018